Update Pharma to Present at the 15th Annual Rodman & Renshaw Global Investment
RENO, Nev., Sept. 6, 2013
RENO, Nev., Sept. 6, 2013 /PRNewswire/ --Update Pharma Inc., today announced
it will be featured as a presenting company at the 15^th Annual Rodman &
Renshaw Global Investment Conference on September 10, 2013 at 3:15 pm in room
7-03 of the Millennium Hotel. The presentation will be webcast live, and the
replay will remain available for 90 days at www.rodm.com.
John Rothman Ph.D., CEO, of Update Pharma, will provide an overview of the
Company's business during the live presentation and will be available to
participate in one-on-one meetings with investors.
About Update Pharma Inc.:
Update Pharma Inc. is developing UPI-928. In the 1980's UPI-928 was developed
by Lederle Laboratories in 44 phase 1, 2 and 3 clinical trials, including 33
clinical trials at the National Cancer Institute. Over 2000 treated patients
demonstrated an acceptable safety profile and clinical activity that was
documented in over 71 peer reviewed publications in which clinical utility was
demonstrated in recurrent or regressive in leukemia, lymphoma, breast and
ovarian cancers. The agent was approved for marketing in France for the
treatment of acute myeloid leukemia (AML). However, Lederle was sold at about
the time of the approval to Wyeth, who did not have a market presence in
oncology. Development was stopped and, despite marketing approval, UPI-928
was never launched. Wyeth was sold shortly thereafter to Pfizer, who did not
re-activate the program. Thus, despite a safety profile that was superior to
related drugs and an extensive body of peer reviewed literature documenting
clinical activity in a number of indications, UPI-928 was never marketed and
was eventually forgotten.
Recent data has shown that UPI-928 also has significant immunologic and
genomic mechanisms of action which contribute to the clinical utility of the
agent. These include, for example, the ability to activate macrophages
sufficient to eliminate tumors in an allogeneic model and the ability to bind
DNA in a manner that displaces telomerase binding proteins and blocks the
action of telomerase, enabling immortal cells to regain a mortal phenotype.
This multi-factorial attack on cancer may ultimately make UPI-928 suited for
combinatorial regimens in which chemotherapeutic agents are combined with
immunologically active and/or genomically active agents.
Update has filed extensive for broad and deep patent protection on UPI-928
based upon the composition of new formulations with better aqueous solubility,
new mechanisms of action, and methods of use that include use with symptom
mitigating agents like Neulasta^® and Neumega^®, and combinatorial regimens
with immuno-modulators or small molecules. The company intends to use
existing regulatory mechanisms to accelerate the development process based
upon the extensive body of historical data.
Certain statements in this Press Release are "forward-looking statements"
within the meaning of the Private Securities Litigation Act of 1995. These
forward-looking statements are based on our current expectations and beliefs
and are subject to a number of risk factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. Such risks and uncertainties include the risk for
the Company to complete its development work, as well as the risks inherent in
commercializing a new product (including technology risks, market risks,
financial risks and implementation risks, and other risks and uncertainties
affecting the Company), as well as other risks that have been disclosed by us
and are customarily disclosed in SEC filings of publicly traded pharmaceutical
companies. We disclaim any intention or obligation to revise any
forward-looking statements, including, without limitation, financial
estimates, whether as a result of new information, future events, or
Read more news from Update Pharma Inc.
SOURCE Update Pharma Inc.
Press spacebar to pause and continue. Press esc to stop.